Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Multiple Sclerosis

  Free Subscription


27.02.2017

1 BMC Neurol
1 Clin Ther
1 J Immunol
1 J Neurol
2 Lancet Neurol
1 Neurology
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMC Neurol

  1. LIMMROTH V, Ziemssen T, Lang M, Richter S, et al
    Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study.
    BMC Neurol. 2017;17:11.
    PubMed     Text format     Abstract available


    Clin Ther

  2. SOINI E, Joutseno J, Sumelahti ML
    Cost-Utility of First-Line Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
    Clin Ther. 2017 Feb 13. pii: S0149-2918(17)30074.
    PubMed     Text format     Abstract available


    J Immunol

  3. LIU R, Ma X, Chen L, Yang Y, et al
    MicroRNA-15b Suppresses Th17 Differentiation and Is Associated with Pathogenesis of Multiple Sclerosis by Targeting O-GlcNAc Transferase.
    J Immunol. 2017 Feb 22. pii: 1601727. doi: 10.4049/jimmunol.1601727.
    PubMed     Text format     Abstract available


    J Neurol

  4. DULAU C, Deloire M, Diaz H, Saubusse A, et al
    Social cognition according to cognitive impairment in different clinical phenotypes of multiple sclerosis.
    J Neurol. 2017 Feb 20. doi: 10.1007/s00415-017-8417.
    PubMed     Text format     Abstract available


    Lancet Neurol

  5. SORMANI MP, Laroni A
    Approved drugs for multiple sclerosis: the challenge of choice.
    Lancet Neurol. 2017 Feb 10. pii: S1474-4422(17)30021.
    PubMed     Text format    

  6. KALINCIK T, Brown JW, Robertson N, Willis M, et al
    Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.
    Lancet Neurol. 2017 Feb 10. pii: S1474-4422(17)30007.
    PubMed     Text format     Abstract available


    Neurology

  7. MOWRY EM, McArthur JC
    PML in natalizumab-treated multiple sclerosis: Modeling errors and risk miscalculations.
    Neurology. 2017 Feb 22. pii: 10.1212/WNL.0000000000003749.
    PubMed     Text format    


    Proc Natl Acad Sci U S A

  8. LI Y, Singer NG, Whitbred J, Bowen MA, et al
    CD6 as a potential target for treating multiple sclerosis.
    Proc Natl Acad Sci U S A. 2017 Feb 16. pii: 201615253.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: